

# Vabysmo (faricimab-svoa)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications	Dosing Limit
Vabysmo (faricimab-svoa) 6 mg vial	<p><b>Diabetic Macular Edema and Neovascular (Wet) Age-Related Macular Degeneration:</b> 6 mg per eye; each eye may be treated as frequently as every 4 weeks</p> <p><b>Macular Edema following retinal vein occlusion (RVO):</b> 6 mg per eye; each eye may be treated every 4 weeks for 6 months</p>

## APPROVAL CRITERIA

Requests for Vabysmo (faricimab-svoa) may be approved if the following criteria are met:

- I. Individual has a diagnosis of one of the following:
  - A. Diabetic Macular Edema (DME) (including DME with diabetic retinopathy of any severity); **OR**
  - B. Established neovascular “wet” age-related macular degeneration; **OR**
  - C. Macular edema following retinal vein occlusion (RVO).

Requests for Vabysmo (faricimab-svoa) may not be approved when the above criteria are not met and for all other indications.

## Key References:

- DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.
- DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
- Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2023; Updated periodically.
- American Academy of Ophthalmology. Preferred Practice Pattern Guidelines: Retinal Vein Occlusions. October 2019. Available at: <https://www.aao.org/preferred-practice-pattern/retinal-vein-occlusions-ppp>.
- American Academy of Ophthalmology. Preferred Practice Pattern Guidelines: Age-Related Macular Degeneration. October 2019. Available at: <https://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp>.
- American Academy of Ophthalmology. Preferred Practice Pattern Guidelines: Diabetic Retinopathy. October 2019. Available at: <https://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp>.
- Finger PT, Chin KJ, Semanova EA. Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study. *Eur J Ophthalmol*. 2016; 26(1):60-66.
- Pulido JS, Flaxel CJ, Adelman RA, Hyman L, Folk JC, Olsen TW. American Academy of Ophthalmology: Retinal Vein Occlusions Preferred Practice Pattern® guidelines. *Ophthalmology*. 2016; 123: 182–208.
- Cheung, C.M.G.; Arnold, J.J.; Holz, F.G.; Park, K.H.; Lai, T.Y.Y.; Larsen, M.; Mitchell, P.; Ohno-Matsui, K.; Chen, S.J.; Wolf, S.; et al. Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management. *Ophthalmology* **2017**, 124, 1690–1711.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.